A share price of Outset Medical Inc [OM] is currently trading at $3.72, up 9.09%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OM shares have gain 4.79% over the last week, with a monthly amount glided 12.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.
From an analyst’s perspective:
Outset Medical Inc [NASDAQ: OM] stock has seen the most recent analyst activity on January 12, 2024, when RBC Capital Mkts downgraded its rating to a Sector Perform and also revised its price target to $6 from $14. Previously, BofA Securities downgraded its rating to Underperform on October 13, 2023, and dropped its price target to $3. On August 17, 2023, CL King initiated with a Neutral rating. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $23 on November 11, 2022. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $20 on July 14, 2022. In a note dated February 17, 2022, Morgan Stanley upgraded an Overweight rating on this stock but restated the target price of $50.
Outset Medical Inc experienced fluctuations in its stock price throughout the past year between $2.73 and $24.13. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Outset Medical Inc [NASDAQ: OM] shares were valued at $3.72 at the most recent close of the market. An investor can expect a potential return of 625.81% based on the average OM price forecast.
Analyzing the OM fundamentals
Trailing Twelve Months sales for Outset Medical Inc [NASDAQ:OM] were 130.38M which represents -4.69% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.27 points at the first support level, and at 2.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.07, and for the 2nd resistance point, it is at 4.42.
Outset Medical Inc [OM] reported earnings per share of -$0.59 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.61/share, meaning a difference of $0.02 and a surprise factor of 3.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.71 per share as compared to estimates of -$0.67 per share, a difference of -$0.04 representing a surprise of -6.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Outset Medical Inc [NASDAQ:OM] is 5.26. Further, the Quick Ratio stands at 4.37, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 1.44, the price to book ratio is 1.52.
Transactions by insiders
Recent insider trading involved Trigg Leslie, Chair and CEO, that happened on Feb 15 when 5320.0 shares were sold. Chief Financial Officer, Ahmed Nabeel completed a deal on Feb 15 to sell 4403.0 shares. Meanwhile, General Counsel Brottem John L. sold 3341.0 shares on Feb 15.
